Floatz logo

Atezolizumab

Gastroesophageal Junction

Arbele Pty Ltdmonoclonal_antibodyPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Gastroesophageal Junction cohort.

Asset / SponsorPhaseRating
Levoleucovorin
Merck Sharp & Dohme LLC
Phase 3BB
Patritumab Deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2CC
her3-dxd
Merck Sharp & Dohme LLC
Phase 1/2CC
Sacituzumab Tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2CC
Cabotamig
Arbele Pty Ltd
Phase 1CC
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
USWM CT, LLC
Phase 1CC

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →